{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:14:37Z","timestamp":1794060877127,"version":"4.8.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"AIRC","doi-asserted-by":"crossref","award":["IG2015-17400"],"award-info":[{"award-number":["IG2015-17400"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"AIRC","doi-asserted-by":"crossref","award":["18603"],"award-info":[{"award-number":["18603"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"AIRC","doi-asserted-by":"crossref","award":["12182"],"award-info":[{"award-number":["12182"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","award":["CPDA-144873"],"award-info":[{"award-number":["CPDA-144873"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EuroNanomed II"},{"name":"Euronanomed III"},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"crossref","award":["Clinic"],"award-info":[{"award-number":["Clinic"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"crossref","award":["Laboratory Integration Program CLIP 2017"],"award-info":[{"award-number":["Laboratory Integration Program CLIP 2017"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cariverona Foundation","award":["Project call 2017"],"award-info":[{"award-number":["Project call 2017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myeloid derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) are two of the major players involved in the inhibition of anti-tumor immune response in cancer patients, leading to poor prognosis. Selective targeting of myeloid cells has therefore become an attractive therapeutic strategy to relieve immunosuppression and, in this frame, we previously demonstrated that lipid nanocapsules (LNCs) loaded with lauroyl-modified gemcitabine efficiently target monocytic MDSCs in melanoma patients. In this study, we investigated the impact of the physico-chemical characteristics of LNCs, namely size and surface potential, towards immunosuppressive cell targeting. We exploited myeloid cells isolated from glioblastoma patients, which play a relevant role in the immunosuppression, to demonstrate that tailored nanosystems can target not only tumor cells but also tumor-promoting cells, thus constituting an efficient system that could be used to inhibit their function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incorporation of different LNC formulations with a size of 100\u00a0nm, carrying overall positive, neutral or negative charge, was evaluated on leukocytes and tumor-infiltrating cells freshly isolated from glioblastoma patients. We observed that the maximum LNC uptake was obtained in monocytes with neutral 100\u00a0nm LNCs, while positively charged 100\u00a0nm LNCs were more effective on macrophages and tumor cells, maintaining at low level the incorporation by T cells. The mechanism of uptake was elucidated, demonstrating that LNCs are incorporated mainly by caveolae-mediated endocytosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We demonstrated that LNCs can be directed towards immunosuppressive cells by simply modulating their size and charge\u00a0thus providing a novel approach to exploit nanosystems for anticancer treatment in the frame of immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12951-020-00589-3","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T08:06:04Z","timestamp":1581926764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules"],"prefix":"10.1186","volume":"18","author":[{"given":"Laura","family":"Pinton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Masetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Vettore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Schibuola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Ingangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Marigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Matha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Benoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Della Puppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bronte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Lollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0707-995X","authenticated-orcid":false,"given":"Susanna","family":"Mandruzzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"issue":"1","key":"589_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1021\/nn5062029","volume":"9","author":"K Shao","year":"2015","unstructured":"Shao K, Singha S, Clemente-Casares X, Tsai S, Yang Y, Santamaria P. Nanoparticle-based immunotherapy for cancer. ACS Nano. 2015;9(1):16\u201330.","journal-title":"ACS Nano"},{"issue":"1","key":"589_CR2","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/s41467-017-01651-9","volume":"8","author":"J Lu","year":"2017","unstructured":"Lu J, Liu X, Liao YP, Salazar F, Sun B, Jiang W, et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun. 2017;8(1):1811.","journal-title":"Nat Commun."},{"key":"589_CR3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jconrel.2016.12.032","volume":"247","author":"H He","year":"2017","unstructured":"He H, Ghosh S, Yang H. Nanomedicines for dysfunctional macrophage-associated diseases. J Control Release. 2017;247:106\u201326.","journal-title":"J Control Release"},{"issue":"7607","key":"589_CR4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396\u2013401.","journal-title":"Nature"},{"key":"589_CR5","first-page":"426028","volume":"2014","author":"Q Jiao","year":"2014","unstructured":"Jiao Q, Li L, Mu Q, Zhang Q. Immunomodulation of nanoparticles in nanomedicine applications. Biomed Res Int. 2014;2014:426028.","journal-title":"Biomed Res Int"},{"issue":"12","key":"589_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nnano.2011.166","volume":"6","author":"H Cabral","year":"2011","unstructured":"Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100\u00a0nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815\u201323.","journal-title":"Nat Nanotechnol"},{"key":"589_CR7","doi-asserted-by":"publisher","first-page":"e1808303","DOI":"10.1002\/adma.201808303","volume":"31","author":"M Ovais","year":"2019","unstructured":"Ovais M, Guo M, Chen C. Tailoring nanomaterials for targeting tumor-associated macrophages. Adv Mater. 2019;31:e1808303.","journal-title":"Adv Mater."},{"key":"589_CR8","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.","journal-title":"Nat Commun."},{"issue":"10","key":"589_CR9","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889\u201396.","journal-title":"Nat Immunol"},{"issue":"7","key":"589_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399\u2013416.","journal-title":"Nat Rev Clin Oncol."},{"key":"589_CR11","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3389\/fimmu.2018.00398","volume":"9","author":"V Fleming","year":"2018","unstructured":"Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol. 2018;9:398.","journal-title":"Front Immunol."},{"issue":"7","key":"589_CR12","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1158\/1535-7163.MCT-06-0289","volume":"5","author":"E Garcion","year":"2006","unstructured":"Garcion E, Lamprecht A, Heurtault B, Paillard A, Aubert-Pouessel A, Denizot B, et al. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol Cancer Ther. 2006;5(7):1710\u201322.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"589_CR13","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.ijpharm.2015.09.062","volume":"495","author":"G Lollo","year":"2015","unstructured":"Lollo G, Vincent M, Ullio-Gamboa G, Lemaire L, Franconi F, Couez D, et al. Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma. Int J Pharm. 2015;495(2):972\u201380.","journal-title":"Int J Pharm"},{"key":"589_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.biomaterials.2016.04.010","volume":"96","author":"MS Sasso","year":"2016","unstructured":"Sasso MS, Lollo G, Pitorre M, Solito S, Pinton L, Valpione S, et al. Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. Biomaterials. 2016;96:47\u201362.","journal-title":"Biomaterials"},{"issue":"2","key":"589_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ijpharm.2013.05.057","volume":"453","author":"S Hirsjarvi","year":"2013","unstructured":"Hirsjarvi S, Sancey L, Dufort S, Belloche C, Vanpouille-Box C, Garcion E, et al. Effect of particle size on the biodistribution of lipid nanocapsules: comparison between nuclear and fluorescence imaging and counting. Int J Pharm. 2013;453(2):594\u2013600.","journal-title":"Int J Pharm"},{"issue":"2","key":"589_CR16","doi-asserted-by":"publisher","first-page":"e85841","DOI":"10.1172\/jci.insight.85841","volume":"1","author":"KS Gabrusiewicz","year":"2016","unstructured":"Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016;1(2):e85841. https:\/\/doi.org\/10.1172\/jci.insight.85841.","journal-title":"JCI Insight."},{"issue":"9","key":"589_CR17","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1016\/j.celrep.2016.10.052","volume":"17","author":"RL Bowman","year":"2016","unstructured":"Bowman RL, Klemm F, Akkari L, Pyonteck SM, Sevenich L, Quail DF, et al. Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep. 2016;17(9):2445\u201359.","journal-title":"Cell Rep."},{"issue":"1","key":"589_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40425-019-0536-x","volume":"7","author":"L Pinton","year":"2019","unstructured":"Pinton L, Masetto E, Vettore M, Solito S, Magri S, D\u2019Andolfi M, et al. The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. J Immunother Cancer. 2019;7(1):58.","journal-title":"J Immunother Cancer."},{"issue":"11","key":"589_CR19","doi-asserted-by":"publisher","first-page":"e1196310","DOI":"10.1080\/2162402X.2016.1196310","volume":"5","author":"Z Wang","year":"2016","unstructured":"Wang Z, Zhang C, Liu X, Wang Z, Sun L, Li G, et al. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncoimmunology. 2016;5(11):e1196310.","journal-title":"Oncoimmunology."},{"issue":"11","key":"589_CR20","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/neuonc\/nox054","volume":"19","author":"AS Berghoff","year":"2017","unstructured":"Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol. 2017;19(11):1460\u20138.","journal-title":"Neuro Oncol."},{"key":"589_CR21","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3389\/fimmu.2018.01004","volume":"9","author":"Z Chen","year":"2018","unstructured":"Chen Z, Hambardzumyan D. Immune Microenvironment in Glioblastoma Subtypes. Front Immunol. 2018;9:1004.","journal-title":"Front Immunol."},{"issue":"6","key":"589_CR22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1023\/A:1016121319668","volume":"19","author":"B Heurtault","year":"2002","unstructured":"Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res. 2002;19(6):875\u201380.","journal-title":"Pharm Res"},{"key":"589_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.tiv.2017.03.007","volume":"41","author":"G Le Roux","year":"2017","unstructured":"Le Roux G, Moche H, Nieto A, Benoit JP, Nesslany F, Lagarce F. Cytotoxicity and genotoxicity of lipid nanocapsules. Toxicol In Vitro. 2017;41:189\u201399.","journal-title":"Toxicol In Vitro"},{"issue":"1","key":"589_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0169-409X(01)00245-9","volume":"54","author":"SV Vinogradov","year":"2002","unstructured":"Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev. 2002;54(1):135\u201347.","journal-title":"Adv Drug Deliv Rev"},{"issue":"13","key":"589_CR25","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1016\/j.biomaterials.2010.01.065","volume":"31","author":"C He","year":"2010","unstructured":"He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657\u201366.","journal-title":"Biomaterials"},{"issue":"44","key":"589_CR26","doi-asserted-by":"publisher","first-page":"9799","DOI":"10.1523\/JNEUROSCI.3126-04.2004","volume":"24","author":"MD Dunning","year":"2004","unstructured":"Dunning MD, Lakatos A, Loizou L, Kettunen M, Ffrench-Constant C, Brindle KM, et al. Superparamagnetic iron oxide-labeled Schwann cells and olfactory ensheathing cells can be traced in vivo by magnetic resonance imaging and retain functional properties after transplantation into the CNS. J Neurosci. 2004;24(44):9799\u2013810.","journal-title":"J Neurosci"},{"issue":"Pt 2","key":"589_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1242\/jcs.00235","volume":"116","author":"N Araki","year":"2003","unstructured":"Araki N, Hatae T, Furukawa A, Swanson JA. Phosphoinositide-3-kinase-independent contractile activities associated with Fcgamma-receptor-mediated phagocytosis and macropinocytosis in macrophages. J Cell Sci. 2003;116(Pt 2):247\u201357.","journal-title":"J Cell Sci"},{"issue":"5","key":"589_CR28","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1083\/jcb.135.5.1249","volume":"135","author":"N Araki","year":"1996","unstructured":"Araki N, Johnson MT, Swanson JA. A role for phosphoinositide 3-kinase in the completion of macropinocytosis and phagocytosis by macrophages. J Cell Biol. 1996;135(5):1249\u201360.","journal-title":"J Cell Biol"},{"issue":"21","key":"589_CR29","doi-asserted-by":"publisher","first-page":"12050","DOI":"10.1073\/pnas.211341698","volume":"98","author":"A Ros-Baro","year":"2001","unstructured":"Ros-Baro A, Lopez-Iglesias C, Peiro S, Bellido D, Palacin M, Zorzano A, et al. Lipid rafts are required for GLUT4 internalization in adipose cells. Proc Natl Acad Sci U S A. 2001;98(21):12050\u20135.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"7738","key":"589_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240\u20135.","journal-title":"Nature"},{"issue":"7738","key":"589_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234\u20139.","journal-title":"Nature"},{"issue":"1","key":"589_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.7150\/thno.21342","volume":"8","author":"H Liu","year":"2018","unstructured":"Liu H, Mai J, Shen J, Wolfram J, Li Z, Zhang G, et al. A Novel DNA Aptamer for dual targeting of polymorphonuclear myeloid-derived suppressor cells and tumor cells. Theranostics. 2018;8(1):31\u201344.","journal-title":"Theranostics."},{"issue":"13","key":"589_CR33","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.7150\/thno.19987","volume":"7","author":"M Kong","year":"2017","unstructured":"Kong M, Tang J, Qiao Q, Wu T, Qi Y, Tan S, et al. Biodegradable hollow mesoporous silica nanoparticles for regulating tumor microenvironment and enhancing Antitumor efficiency. Theranostics. 2017;7(13):3276\u201392.","journal-title":"Theranostics."},{"key":"589_CR34","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nano.2018.11.015","volume":"16","author":"C Wu","year":"2019","unstructured":"Wu C, Muroski ME, Miska J, Lee-Chang C, Shen Y, Rashidi A, et al. Repolarization of myeloid derived suppressor cells via magnetic nanoparticles to promote radiotherapy for glioma treatment. Nanomedicine. 2019;16:126\u201337.","journal-title":"Nanomedicine."},{"key":"589_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jconrel.2018.12.041","volume":"295","author":"AM Ledo","year":"2019","unstructured":"Ledo AM, Sasso MS, Bronte V, Marigo I, Boyd BJ, Garcia-Fuentes M, et al. Co-delivery of RNAi and chemokine by polyarginine nanocapsules enables the modulation of myeloid-derived suppressor cells. J Control Release. 2019;295:60\u201373.","journal-title":"J Control Release"},{"issue":"5\u20136","key":"589_CR36","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1080\/1061186X.2018.1547733","volume":"27","author":"G Lollo","year":"2019","unstructured":"Lollo G, Matha K, Bocchiardo M, Bejaud J, Marigo I, Virgone-Carlotta A, et al. Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules. J Drug Target. 2019;27(5\u20136):634\u201345.","journal-title":"J Drug Target."},{"issue":"28","key":"589_CR37","doi-asserted-by":"publisher","first-page":"6781","DOI":"10.1016\/j.biomaterials.2011.05.067","volume":"32","author":"C Vanpouille-Box","year":"2011","unstructured":"Vanpouille-Box C, Lacoeuille F, Belloche C, Lepareur N, Lemaire L, LeJeune JJ, et al. Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)Re-lipid nanocapsules. Biomaterials. 2011;32(28):6781\u201390.","journal-title":"Biomaterials"},{"issue":"2","key":"589_CR38","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.nano.2009.10.001","volume":"6","author":"D Alizadeh","year":"2010","unstructured":"Alizadeh D, Zhang L, Hwang J, Schluep T, Badie B. Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas. Nanomedicine. 2010;6(2):382\u201390.","journal-title":"Nanomedicine."},{"issue":"2","key":"589_CR39","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/ijms19020436","volume":"19","author":"S Roesch","year":"2018","unstructured":"Roesch S, Rapp C, Dettling S, Herold-Mende C. When immune cells turn bad-tumor-associated microglia\/Macrophages in glioma. Int J Mol Sci. 2018;19(2):436.","journal-title":"Int J Mol Sci"},{"key":"589_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.smim.2017.09.007","volume":"34","author":"TG Dacoba","year":"2017","unstructured":"Dacoba TG, Olivera A, Torres D, Crecente-Campo J, Alonso MJ. Modulating the immune system through nanotechnology. Semin Immunol. 2017;34:78\u2013102.","journal-title":"Semin Immunol"},{"issue":"9","key":"589_CR41","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941\u201351.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"589_CR42","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.nec.2012.04.006","volume":"23","author":"EK Nduom","year":"2012","unstructured":"Nduom EK, Bouras A, Kaluzova M, Hadjipanayis CG. Nanotechnology applications for glioblastoma. Neurosurg Clin N Am. 2012;23(3):439\u201349.","journal-title":"Neurosurg Clin N Am"},{"issue":"10","key":"589_CR43","doi-asserted-by":"publisher","first-page":"6562","DOI":"10.4049\/jimmunol.0803831","volume":"182","author":"S Mandruzzato","year":"2009","unstructured":"Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, et al. IL4Ralpha\u2009+\u2009myeloid-derived suppressor cell expansion in cancer patients. J Immunol. 2009;182(10):6562\u20138.","journal-title":"J Immunol."}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-020-00589-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12951-020-00589-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-020-00589-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T11:27:37Z","timestamp":1613561257000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-020-00589-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1186\/s12951-020-00589-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.18853\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.18853\/v2","asserted-by":"object"}]},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]},"assertion":[{"value":"9 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethical committee of the IOV-IRCCS and of Padova University Hospital approved all experiments and all patients gave their informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}